Shearman & Sterling represented Cowen and Company as sales agent in connection with the commencement of a U.S. at-the-market equity offering program by Nkarta to offer and sell common stock, having an aggregate offering price of up to $150,000,000.

Nkarta, headquartered in South San Francisco, is a clinical stage biopharmaceutical company focused on combining its natural killer (NK) cell expansion and cryopreservation platform with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer.

The Team